Not yet recruiting
Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
NCT07539610
- Conditions
- B Acute Lymphoblastic Leukemia/Lymphoma, B-Acute Lymphoblastic Leukemia, Burkitt Lymphoma, +16 more
- Locations
-
- Institute of Hematology, Chinese Academy of Medical Sciences & Hospital of Hematology, Chinese Academy of Medical Sciences Tianjin, Tianjin Municipality, China